Study for Treatment of Cancer in Children With Ataxia-telangiectasia
Ataxia-Telangiectasia
About this trial
This is an interventional treatment trial for Ataxia-Telangiectasia focused on measuring Ataxia, alphafetoprotein
Eligibility Criteria
Inclusion Criteria: Patient must have a diagnosis of Ataxia-Telangiectasia (A-T). Patient must have a diagnosis of either acute lymphoblastic leukemia (ALL) or lymphoma (non-Hodgkin lymphoma or Hodgkin's disease). Patients with other malignancies (solid tumors, rare malignancies, or relapsed hematopoietic malignancies) will be eligible for the biologic studies of this protocol; they will receive best clinical management chemotherapy. Patients do not have to be previously untreated. If prior chemotherapy has already started (up through induction), therapy will be continued according to protocol at a clinically appropriate time point. Exclusion Criteria: Patients who do not have a diagnosis of Ataxia Telangiectasia (A-T).
Sites / Locations
- St. Jude Children's Research Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm 5
Other
Other
Other
Other
Other
1
2
3A
3B
4
Acute Lymphoblastic Leukemia (ALL) Low Risk
Acute Lymphoblastic Leukemia (ALL) - High Risk
B-Cell Non-Hodgkins Lymphoma (Group A)
B-Cell Non-Hodgkins Lymphoma (Group B)
Hodgkins Disease